Seasonal Influenza Vaccines: Forecast in Asia-Pacific Markets to 2028

2019-12-31
Price :
Published : Dec-2019
No. of Pages : 104

Seasonal Influenza Vaccines: Forecast in Asia-Pacific Markets to 2028

Summary

Seasonal influenza is a viral infection that occurs annually in the winter months from December to March/April in the Northern Hemisphere and from May to August/September in the Southern Hemisphere, though most of India follows Southern Hemisphere seasonality Two types of influenza virus, type A and B, are responsible for the majority of seasonal influenza infections in humans, and due to frequent virus mutations annual vaccination is recommended. The WHO estimates three to five million cases of severe seasonal influenza infections and 290,000 to 650,000 influenza-related respiratory deaths, most of them in the elderly population. Therefore, many countries recommend annual immunization against seasonal influenza, especially for high-risk groups such as young children, pregnant women, elderly people, and people with chronic diseases, but seasonal influenza is not on the national immunization schedule in China and India.

Immunization provides the best protection against the influenza virus and vaccines have been available for decades with a recent switch from trivalent to quadrivalent vaccines that protect against each two influenza type A and two B strains. Traditionally, seasonal influenza vaccines have been produced in eggs, but a slow manufacturing process and viral egg-adaptations have led to a push for cell-based and recombinant vaccine production methods in recent years.

During the 10-year forecast period, there are nine pipeline products that are on track to launch, driving a forecast growth in the 3GM from $914M in 2018 to $1.05B in 2028, which represents a CAGR of 1.4%.

The late stage pipeline for seasonal influenza vaccines in the 3GM includes the first quadrivalent seasonal influenza vaccines in China from Sinovac, Chongqing Zhifei, and Wuhan, as well as a quadrivalent formulation of Fluad. Quadrivalent live-attenuated vaccines will launch in India (from the Serum Institute) and Japan (AstraZeneca’s FluMist, licensed by Daiichi Sankyo). Furthermore, two new inactivated quadrivalent vaccines from Biken and Denka Seiken will launch during the forecast period, as well as a novel plant-based influenza vaccine in Japan.

Medicago’s MDG-2271 will be the first non-egg-based vaccine to launch in the 3GM, addressing the urgent unmet need of influenza vaccine efficacy by shortening production time and minimizing virus mutations.

Another major unmet need in the 3GM is a high vaccination rate and the lack of government support for seasonal influenza immunization in China and India, resulting in vaccination rates around 2%. Vaccination rates in Japan are projected to remain low due to vaccine hesitancy and skepticism.

Key Questions Answered –
– How will the seasonal influenza vaccine market landscape in the 3GM (China, India Japan) change from 2018-2028?
– What are the most promising late-stage pipeline products for seasonal influenza vaccination?
– How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing immunization options?
– What are the remaining unmet needs in seasonal influenza immunization?
– What drivers and barriers will affect seasonal influenza vaccine sales in the 3GM over the forecast period?

Scope

– Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline Seasonal influenza market revenue from 2018-2028. Annual cost of immunization and major pipeline product sales in this forecast period are included.
– Key topics covered include current vaccination options, unmet needs and opportunities, and the drivers and barriers affecting seasonal influenza vaccine sales in the 3GM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the APAC seasonal influenza vaccine market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the APAC seasonal influenza vaccine market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Organ Preservation Market by Solution (UW/Custodiol HTK/Perfadex), Technique (Static Cold Storage/Hypothermic Machine Perfusion/ Normothermic Machine Perfusion), Organ Type (Kidneys/Liver/Lungs/Heart), Region – Global Forecast to 2024

“The organ preservation market is projected to grow at a CAGR of 6.5%.” The global organ preservation market is projected to reach USD 284 million by 2024 from USD 207 million in 2019, at a CAGR of 6.5%. The growth of the organ preservation market is mainly driven by the increasing incidence of multi-organ failure, the growing geriatric population, the rising number of organ transplants and organ donors, and increasing initiatives to encourage organ donations. However, the high cost of organ transplantations and religious concerns in specific geographies are expected to limit market growth to a certain extent. “The University of Wisconsin (UW) holds the market share in the solutions market.” Based on the Solution, the segment is divided into UW, Custodial HTK, Perfadex and......
$5650

Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User (Hospital) – Global Forecast to 2025

“The global transplant diagnostics market is projected to grow at a CAGR of 7.2% during the forecast period.” The transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%. The demand for transplant diagnostic products is expected to grow due to technological advancements in the field of transplant diagnostics and increasing public-private funding for target research activities. The transplant diagnostics market is segmented on product, technology, application, transplant type, end user, and region. “The independent reference laboratories segment accounted for the largest share of the transplant diagnostics market, by end user, in 2019.” Based on end user, the transplant diagnostics market is segmented into i......
$5650

mHealth Solutions Market by Connected Devices (Glucose & Blood Pressure Monitor, Peak Flow Meter, Pulse Oximeter), Apps (Weight Loss, Women Health, Diabetes Management, Mental Health), Services (Remote Monitoring, Consultation) – Global Forecast to 2025

“The mHealth solutions market is expected to grow at a CAGR of 33.3% during the forecast period.” The global mHealth solutions market is projected to reach USD 213.6 billion by 2025 from USD 50.82 billion in 2020, at a high CAGR of 33.3% during the forecast period of 2020 to 2025.The growing adoption of smartphones, increasing penetration of 3G/4G networks, increasing utilization of connected devices and mHealth apps for the management of chronic diseases, rising focus on cost containment in healthcare delivery, rising focus on patient-centric healthcare delivery, and the increasing demand for home healthcare services are some of the key factors driving the greater uptake of mobile technologies among both patients and healthcare professionals. “Based on product and service, the......
$5650

Graft Versus Host Disease: Epidemiology Forecast to 2028

Graft Versus Host Disease: Epidemiology Forecast to 2028 Summary GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation. GlobalData epidemiologists utilized historical HSCT data available through c......
$3995

Healthcare Fraud Analytics Market by Solution Type (Descriptive, Predictive, Prescriptive), Application (Insurance Claim (Postpayment, Prepayment), Payment Integrity), Delivery (On-premise, Cloud), End User (Insurance, Government) – Global Forecast to 2025

The healthcare fraud analytics market is projected to reach USD 4.6 billion by 2025 from USD 1.2 billion in 2020 at a CAGR of 29.8%. The emergence of social network analytics, the adoption of technologies such as AI and blockchain, and the growing use of healthcare analytics for fraud detection in emerging nations like the APAC provide growth opportunities in this market. However, the time-consuming deployment of these solutions and the need for frequent updates are some challenges faced by end users of this market. The on-demand segment is projected to witness the highest growth during the forecast period On the basis of delivery model, the healthcare fraud analytics market is segmented into on-premise and on-demand models. The on-demand models include the cloud-based and web-based......
$5650

Women’s Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) – Global forecast to 2024

“Growing incidence of chronic health conditions among women and the demand in contraceptives to prevent unintended pregnancies are the key factors driving the women’s healthcare market.” The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period. Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth. “Prolia is the larg......
$5650

Virtual/Augmented Reality in Healthcare – Thematic Research

Virtual/Augmented Reality in Healthcare - Thematic Research Summary Virtual reality (VR) and augmented reality (AR) technologies have been traditionally associated with the entertainment industry, with virtual and immersive environments used for gamers, product designers, and architects. However, increasing healthcare expenditure and the need for cutting-edge technologies to aid the development of novel therapies and diagnostics have fueled the need for this technology in the healthcare industry. As the technology advances and with the availability of cheaper, more user-friendly VR/AR headsets, the barriers to its widespread use in healthcare are beginning to fall. While still in the early stages of adoption, there are myriad possibilities for VR/AR technology in the healthcare sector, i......
$1950

Virtual Care – Thematic Research

Virtual Care - Thematic Research Summary Virtual Care is the intersection between digital technologies and healthcare delivery systems. By integrating new and existing digital technologies such as telehealth, connected medical devices, remote monitoring, mobile device apps, and electronic health records, healthcare systems can expand their services to patient populations whenever and however is most convenient to each individual patient. By allowing patients to interact with their healthcare providers digitally, patients are encouraged to seek out continual care without having to incur the consequences of unnecessary travel, limited access to care services, or lost days of work. Virtual Care offerings allow healthcare systems to greatly expand their patient population reach. This is esp......
$1950

Connected Care – Thematic Research

Connected Care - Thematic Research Summary Connected Care is the continued and emerging integration of smart technologies into the healthcare system. By linking all of the currently available healthcare streams of information to emerging technologies, healthcare systems can vastly increase their efficiency and offerings to patient populations. Traditionally, healthcare systems are compartmentalized units of services that link together to provide patients with solutions to their illnesses and conditions. Digital technologies are enabling healthcare services become fully integrated in order to both optimize care delivery and enable more targeted and seamless healthcare. Paramedics with the ability to identify patients in distress, access their health records electronically, and stabilize ......
$1950

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – United Arab Emirates

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape -UAE". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the UAE. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape, and healthcare infrastructure of the UAE. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-h......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy